Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis.

Arteriosclerosis, thrombosis, and vascular biology - 1 Mar 1999

Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci P M

Abstract excerpt

Single-point mutations in the gene coding for prothrombin (factor II:A20210) or factor V (factor V:A1691) are associated with an increased risk of venous thromboembolism. The use of oral contraceptives is also a strong and independent risk factor for the disease, and the interaction between factor V:A1691 and oral contraceptives greatly increases the risk. No information is available about the interaction between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Contraceptives, Oral
Share to Factor V

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterozygote

Share to Homozygote

Share to Point Mutation

Share to Prothrombin

Share to Risk Factors

Share to Venous Thrombosis

Source

Identifiers

PMID: 10073976
DOI: 10.1161/01.atv.19.3.700

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis.PMID 10073976Read ↗

Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use.Semantic proximity Read ↗

Combined Effect of Factor V Leiden and Prothrombin 20210A on the Risk of Venous ThromboembolismSemantic proximity Read ↗

Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis.Semantic proximity Read ↗

Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis.Semantic proximity Read ↗

The role of genetics in the risk of thromboembolism: prothrombin 20210A and oral contraceptive therapy.Semantic proximity Read ↗

Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls.Semantic proximity Read ↗

Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis.Semantic proximity Read ↗

The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels.Semantic proximity Read ↗

Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.Semantic proximity Read ↗

Venous thromboembolism, oral contraceptives and high prothrombin levels.Semantic proximity Read ↗

Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis.Semantic proximity Read ↗

High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.